AVTR Quote, Financials, Valuation and Earnings

Azenta has a net margin of 29.67% compared to Avantor's net margin of -9.04%. Avantor's return on equity of 12.92% beat Azenta's return on equity of -7.97%.

Avantor has a consensus price target of $20.98, signalling upside risk potential of 62.29%. On the other hand Azenta has an analysts' consensus of $51.60 which suggests that it could grow by 93.04%. Given that Azenta has higher upside potential than Avantor, analysts believe Azenta is more attractive than Avantor.

Avantor has a beta of 1.236, which suggesting that the stock is 23.603% more volatile than S&P 500. In comparison Azenta has a beta of 1.660, suggesting its more volatile than the S&P 500 by 66.003%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avantor pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Avantor quarterly revenues are $1.7B, which are larger than Azenta quarterly revenues of $147.5M. Avantor's net income of $500.4M is higher than Azenta's net income of -$13.3M. Notably, Avantor's price-to-earnings ratio is 12.43x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.30x versus 2.08x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 29.67% compared to Avantor's net margin of -107.24%. Avantor's return on equity of 12.92% beat Bio-Rad Laboratories's return on equity of -23.87%.

Avantor has a consensus price target of $20.98, signalling upside risk potential of 62.29%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $353.17 which suggests that it could grow by 45.56%. Given that Avantor has higher upside potential than Bio-Rad Laboratories, analysts believe Avantor is more attractive than Bio-Rad Laboratories.

Avantor has a beta of 1.236, which suggesting that the stock is 23.603% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 1.119, suggesting its more volatile than the S&P 500 by 11.924%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avantor pays -- of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend.

Avantor quarterly revenues are $1.7B, which are larger than Bio-Rad Laboratories quarterly revenues of $667.5M. Avantor's net income of $500.4M is higher than Bio-Rad Laboratories's net income of -$715.8M. Notably, Avantor's price-to-earnings ratio is 12.43x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.30x versus 2.67x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 29.67% compared to Avantor's net margin of 1.4%. Avantor's return on equity of 12.92% beat Bruker's return on equity of 6.78%.

Avantor has a consensus price target of $20.98, signalling upside risk potential of 62.29%. On the other hand Bruker has an analysts' consensus of $60.13 which suggests that it could grow by 53.9%. Given that Avantor has higher upside potential than Bruker, analysts believe Avantor is more attractive than Bruker.

Avantor has a beta of 1.236, which suggesting that the stock is 23.603% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.51% to investors and pays a quarterly dividend of $0.05 per share. Avantor pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Avantor quarterly revenues are $1.7B, which are larger than Bruker quarterly revenues of $979.6M. Avantor's net income of $500.4M is higher than Bruker's net income of $13.7M. Notably, Avantor's price-to-earnings ratio is 12.43x while Bruker's PE ratio is 51.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.30x versus 1.73x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 29.67% compared to Avantor's net margin of 0.07%. Avantor's return on equity of 12.92% beat Harvard Bioscience's return on equity of -18.36%.

Avantor has a consensus price target of $20.98, signalling upside risk potential of 62.29%. On the other hand Harvard Bioscience has an analysts' consensus of $4.50 which suggests that it could grow by 1093.95%. Given that Harvard Bioscience has higher upside potential than Avantor, analysts believe Harvard Bioscience is more attractive than Avantor.

Avantor has a beta of 1.236, which suggesting that the stock is 23.603% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.468, suggesting its more volatile than the S&P 500 by 46.794%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avantor pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Avantor quarterly revenues are $1.7B, which are larger than Harvard Bioscience quarterly revenues of $24.6M. Avantor's net income of $500.4M is higher than Harvard Bioscience's net income of $18K. Notably, Avantor's price-to-earnings ratio is 12.43x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.30x versus 0.17x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.